T cells are central drivers of inflammation across autoimmune and inflammatory diseases, yet current therapies inadequately target pathogenic T-cell pathways, limiting durable disease control. In a recent study published in Signal Transduction and Targeted Therapy, a team led by Thomas Helleday and Theodora Manolakou, identified a novel, targetable transcriptional-metabolic axis that sustains inflammatory T-cell responses. In an interview by Gustav Ceder, Helleday discusses the novel findings and ongoing lines of research...Read more